DYNE THERAPEUTICS INC (DYN)
Sector: Health Care
2026 Annual Meeting Analysis
DYNE THERAPEUTICS INC · Meeting: June 5, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Three Class III Directors
Lubner has served since March 2020 and brings strong financial expertise as a former biotech CFO and audit committee financial expert; DYN's 3-year return of +79.7% outperforms XBI (SPDR S&P Biotech ETF) by +13.2 percentage points, well below the 65-point threshold needed to trigger an against vote, and no other policy flags (overboarding, attendance, independence, or family relationship issues) apply.
Posner joined the board in October 2025, less than 24 months ago, which fully exempts him from the TSR trigger under policy; he brings relevant financial and biotech board experience, and no other policy flags apply.
Rhodes has served since December 2017 and brings deep company knowledge as founding CEO and chairman; DYN's 3-year return of +79.7% outperforms XBI (SPDR S&P Biotech ETF) by +13.2 percentage points, far below the 65-point threshold needed to trigger an against vote, and no other policy flags apply.
All three Class III director nominees pass the policy screens — DYN's strong 3-year stock performance outpaces the XBI (SPDR S&P Biotech ETF) benchmark by +13.2 percentage points, which is well below the 65-point underperformance threshold required to trigger a negative vote; no overboarding, attendance, independence, or family relationship concerns were identified for any nominee.
Say on Pay
✓ FORCEO
John G. Cox
Total Comp
$2,076,868
Prior Support
N/A
The CEO's total reported compensation of approximately $2.1 million for 2025 is modest and well within benchmark expectations for a CEO at a $3.1 billion clinical-stage biotech company, reflecting a year in which no annual equity grant was made to the CEO (the company shifted its equity grant cycle to Q1 of the following year). The company has a meaningful clawback policy, performance-based cash bonuses tied to specific clinical and operational goals scored at 95%, and supplemental stock option grants in 2025 included a market-price hurdle requiring the stock to reach $20 before options become exercisable, demonstrating a genuine link between pay and performance. DYN's stock returned +75.3% over the past year and +79.7% over three years, outperforming XBI (SPDR S&P Biotech ETF) on both timeframes, confirming that incentive pay was earned in a period of strong shareholder returns.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
6 yrs
Audit Fees
$1,181,325
Non-Audit Fees
$0
Deloitte & Touche LLP has served as DYN's auditor since 2020 (approximately 6 years), well below the 25-year tenure threshold; the fee table discloses only audit fees of $1,181,325 with zero non-audit fees, meaning the non-audit fee ratio is 0%, far below the 50% threshold that would raise independence concerns; Deloitte is a Big 4 firm appropriate for a $3.1 billion public company.
Overall Assessment
Dyne Therapeutics' 2026 annual meeting ballot is straightforward and largely uncontroversial — all three director nominees pass policy screens, CEO pay is modest and well-structured relative to strong stock performance, Deloitte's audit fees are clean with zero non-audit fees, and the two charter amendments are appropriate housekeeping measures for a growing clinical-stage biotech. No stockholder proposals were identified in the filing, and all proposals are recommended FOR.